David R. Pelizzon, a director and 10% owner of OrthoPediatrics Corp, filed a Form 4 on September 4, 2026, reporting the sale of 22,500 shares of common stock on September 2, 2026, executed through Squadron Capital LLC.
Key Highlights
- Shares sold: 22,500 shares of OrthoPediatrics Corp (NASDAQ:KIDS) common stock were disposed of on September 2, 2026.
- Weighted average price: $23.35 per share, with individual transactions ranging from $23.01 to $23.74, inclusive.
- Stated reason: According to the filing, the sale "was undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses."
- Indirect beneficial ownership following transaction: 6,504,133 shares held indirectly through Squadron Capital LLC.
- Direct beneficial ownership: 44,384 shares held directly, including restricted stock awards totaling 17,959 shares.
- Beneficial ownership disclaimer: Pelizzon "expressly disclaims beneficial ownership" of the Squadron-held shares, except to the extent of his pecuniary interest therein.
Squadron Capital Sale and Pelizzon's Ownership Position at OrthoPediatrics
According to the Form 4 filed with the SEC, David R. Pelizzon, identified as both a director and a 10% owner of OrthoPediatrics Corp, reported a single disposition transaction. On September 2, 2026, Squadron Capital LLC sold 22,500 shares of OrthoPediatrics common stock at a weighted average price of $23.35. The filing discloses that the shares were sold across multiple transactions at prices ranging from $23.01 to $23.74, inclusive, and that full per-transaction detail is available upon request to the issuer, any security holder, or SEC staff.
The filing states that Pelizzon serves as President and a member of the Managing Committee of Squadron Capital LLC, through which he may be deemed the beneficial owner of 6,504,133 shares held indirectly following the reported transaction. The filing includes an express disclaimer that this attribution "shall not be deemed to be an admission of beneficial ownership for purposes of Section 16 or for any other purpose." In addition to the indirect position, the filing reports 44,384 shares held directly by Pelizzon, a figure that the filing notes includes restricted stock awards totaling 17,959 shares.
The transaction was signed by Daniel J. Gerritzen as Attorney-in-Fact on September 4, 2026, the same date the form was filed. No Rule 10b5-1 plan checkbox was indicated for this transaction.
What Was Disclosed
The filing discloses a sale of 22,500 OrthoPediatrics common shares by Squadron Capital LLC on September 2, 2026, at a weighted average price of $23.35, reported by director and 10% owner David R. Pelizzon, with remaining indirect and direct ownership positions also detailed.




Please wait processing your request...